154 related articles for article (PubMed ID: 38170160)
1. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC; Garralda E; Schöffski P; Hong DS; Siu LL; Martin M; Maur M; Hui R; Soo RA; Chiu J; Zhang T; Ma B; Kyi C; Tan DS; Cassier PA; Sarantopoulos J; Weickhardt A; Carvajal RD; Spratlin J; Esaki T; Rolland F; Akerley W; Deschler-Baier B; Rispoli L; Samant TS; Chowdhury NR; Gusenleitner D; Kwak EL; Askoxylakis V; De Braud F
Oncoimmunology; 2024; 13(1):2290787. PubMed ID: 38170160
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Schöffski P; Tan DSW; Martín M; Ochoa-de-Olza M; Sarantopoulos J; Carvajal RD; Kyi C; Esaki T; Prawira A; Akerley W; De Braud F; Hui R; Zhang T; Soo RA; Maur M; Weickhardt A; Krauss J; Deschler-Baier B; Lau A; Samant TS; Longmire T; Chowdhury NR; Sabatos-Peyton CA; Patel N; Ramesh R; Hu T; Carion A; Gusenleitner D; Yerramilli-Rao P; Askoxylakis V; Kwak EL; Hong DS
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217575
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
Di Giacomo AM; Schenker M; Medioni J; Mandziuk S; Majem M; Gravis G; Cornfeld M; Ranganathan S; Lou S; Csoszi T
ESMO Open; 2024 Mar; 9(3):102387. PubMed ID: 38401247
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C; Cassier P; Zamarin D; Machiels JP; Perez Gracia JL; Stephen Hodi F; Taus A; Martinez Garcia M; Boni V; Eder JP; Hafez N; Sullivan R; Mcdermott D; Champiat S; Aspeslagh S; Terret C; Jegg AM; Jacob W; Cannarile MA; Ries C; Korski K; Michielin F; Christen R; Babitzki G; Watson C; Meneses-Lorente G; Weisser M; Rüttinger D; Delord JP; Marabelle A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577503
[TBL] [Abstract][Full Text] [Related]
7. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
9. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
10. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Weiss SA; Djureinovic D; Jessel S; Krykbaeva I; Zhang L; Jilaveanu L; Ralabate A; Johnson B; Levit NS; Anderson G; Zelterman D; Wei W; Mahajan A; Trifan O; Bosenberg M; Kaech SM; Perry CJ; Damsky W; Gettinger S; Sznol M; Hurwitz M; Kluger HM
Clin Cancer Res; 2021 Sep; 27(17):4757-4767. PubMed ID: 34140403
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Brahmer JR; Drake CG; Wollner I; Powderly JD; Picus J; Sharfman WH; Stankevich E; Pons A; Salay TM; McMiller TL; Gilson MM; Wang C; Selby M; Taube JM; Anders R; Chen L; Korman AJ; Pardoll DM; Lowy I; Topalian SL
J Clin Oncol; 2010 Jul; 28(19):3167-75. PubMed ID: 20516446
[TBL] [Abstract][Full Text] [Related]
13. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
14. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
[TBL] [Abstract][Full Text] [Related]
15. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
[TBL] [Abstract][Full Text] [Related]
16. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
17. First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R; Conlon K; McNeel DG; Wang-Gillam A; Gupta S; Wesolowski R; Chaudhari M; Hassounah N; Lee JB; Ho Lee L; O'Keeffe JA; Lewis N; Pavlakis GN; Thompson JA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907221
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Brito ABC; Camandaroba MPG; de Lima VCC
Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
[TBL] [Abstract][Full Text] [Related]
19. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K
Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187
[TBL] [Abstract][Full Text] [Related]
20. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Janku F; Kim TM; Iyer G; Spreafico A; Elez E; de Jonge M; Yamamoto N; van der Wekken AJ; Ascierto PA; Maur M; Marmé F; Kiladjian JJ; Basu S; Baffert F; Buigues A; Chen C; Cooke V; Giorgetti E; Kim J; McCarthy F; Moschetta M; Dummer R
Eur J Cancer; 2024 Jan; 196():113458. PubMed ID: 38039779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
